Investigating how certain patients with schizophrenia respond to clozapine treatment
3/5 Selective Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
This study is looking at how different groups of people with schizophrenia, based on specific biological markers, respond to the medication clozapine, to help find out who might benefit the most from it, especially those with more severe symptoms and lower cognitive function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11093922 on NIH RePORTER |
What this research studies
This research focuses on understanding how specific subgroups of patients with schizophrenia, defined by unique biomarkers, respond to the antipsychotic medication clozapine. By utilizing a large library of biomarkers from over 3000 individuals, the study aims to identify which patients, particularly those with low cognition and high symptoms, may benefit most from clozapine. The approach involves monitoring neurobiological characteristics rather than just symptoms to improve treatment outcomes. The goal is to enhance diagnostic precision and therapeutic decisions for individuals suffering from psychosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schizophrenia who exhibit low cognitive function and high symptom severity.
Not a fit: Patients who do not have schizophrenia or those who do not fit the specific biomarker-defined subgroups may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with schizophrenia, particularly those who are currently underserved by existing medications.
How similar studies have performed: Other research has shown promise in using biomarker-defined subgroups to tailor treatments for psychiatric conditions, suggesting that this approach could yield significant advancements.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Pearlson, Godfrey D — Yale University
- Study coordinator: Pearlson, Godfrey D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.